Study No.: Title: Rationale: Phase Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
|
|
- Lee Ray
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: LAM30007 Title: Open-Label, Multicenter, Randomized Trial to Evaluate the Development of Components of Polycystic Ovary Syndrome (PCOS) in Female Subjects Initiating Lamotrigine or Valproate Either as Monotherapy for Newly Diagnosed Epilepsy or as Adjunctive Therapy for Inadequately Controlled Epilepsy Rationale: Women with epilepsy are more likely to experience polycystic ovary syndrome (PCOS) than are women in the general population. PCOS is a reproductive endocrine disorder characterized by signs and symptoms of androgen excess and associated with metabolic and cardiovascular abnormalities. However, there is little prospective data regarding PCOS in women taking antiepileptic drugs (AEDs). This study was designed to address the paucity of prospective data about the prevalence and development of components of PCOS in women with epilepsy starting treatment with lamotrigine () or valproate (). Phase: IV Study Period: 09Nov Feb2004 Study Design: Open-label, randomized, multicenter study following changes in menstrual, endocrine, and metabolic function in women who initiated either or either as monotherapy for newly diagnosed/untreated epilepsy or as adjunctive therapy for inadequately controlled epilepsy. Centres: 76 centers in 16 countries Indication: Epilepsy Treatment: at mg/day depending on initial or adjunctive therapy and background AED; at 1000 mg/day not to exceed 60 mg/kg/day Objectives: To determine the development of symptoms of polycystic ovary syndrome (PCOS) in women with epilepsy who were randomized 1:1 to receive or as monotherapy or adjunctive therapy for 1 year. Primary Outcome/Efficacy Variable: The proportion of subjects in each treatment group who developed PCOS symptoms at any time during the study. PCOS symptoms were defined as: Ovulatory dysfunction - the presence of >2 anovulatory cycles as measured by urinary pregnanediol glucuronide assays during two 3-month periods during the study. Hyperandrogenism - defined as total or free serum testosterone, or dehydroepiandrosterone sulfate (DHEA-S) concentration exceeding the 95 th percentile of regularly ovulating women in the early follicular phase (days 1 to 6) of the menstrual cycle. Secondary Outcome/Efficacy Variable(s): The proportion of subjects with polycystic ovaries (PCO), defined as sonographic evidence of 10 peripherally oriented 2- to 8-mm cysts surrounding an increased stroma in at least 1 ovary as determined by a central sonographer The proportion of subjects with PCOS defined by the presence of both ovulatory dysfunction and hyperandrogenism The proportion of subjects with anovulatory menstrual cycles Development of menstrual irregularities Changes from the Screening Visit to the End-of-Study Visit in concentrations of serum androgens (i.e., total and free testosterone, androstenedione, and DHEA-S) and sex-hormone binding globulin (SHBG) Changes from the Screening Visit to the End-of-Study Visit in concentrations of serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and in the LH/FSH ratio Changes from the Screening Visit to the End-of-Study Visit in concentrations of serum lipids (i.e., total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, and triglycerides) The proportion of subjects with hyperinsulinemia, defined as a fasting measurement above the upper limit of the normal range Changes from the Screening Visit to the End-of-Study Visit in concentrations of serum insulin (under both fasting conditions and during the 2-hour glucose-loading test) Changes from the Screening Visit to the End-of-Study Visit in weight Changes from the Screening Visit to the End-of-Study Visit in body mass index (BMI) Changes from the Screening Visit to the End-of-Study Visit in seizure frequency Changes from the Screening Visit to the End-of-Study Visit in health-related quality of life as measured by the SEALS (Side Effect and Life Satisfaction Scale) and stress questionnaires Among women who had PCO and/or hyperandrogenism at the Screening Visit, the proportion of subjects with development or aggravation of additional components of PCOS Statistical Methods: The Intent-to-Treat (ITT) efficacy population was defined as all randomized subjects who 1
2 received at least one dose of study drug who were found to not have components of PCOS at screen (i.e. hyperandrogenism). The Screen PCOS population was defined as all randomized subjects who received at least one dose of study drug who had components of PCOS at screen (i.e. hyperandrogenism).the safety population was defined as all randomized subjects who received at least one dose of study drug. The primary efficacy endpoint, the proportion of subjects who developed PCOS symptoms, was compared between treatment groups using the Mantel-Haenszel Chi-Square test, adjusted for grouped center and epilepsy at enrollment (i.e., newly diagnosed/untreated or inadequately controlled). Ovulatory dysfunction, PCOS (both hyperandrogenism and ovulatory dysfunction), and PCO via sonography were analyzed in the same manner as the primary endpoint. Estimates of treatment effect were provided using odds ratios and 95% confidence intervals (CIs). Changes from screening were analyzed using analysis of covariance (ANCOVA), where screening values served as a covariate. 95% confidence intervals around treatment group differences were constructed. If underlying assumptions did not hold, then the appropriate non-parametric analogs (i.e. non-parametric ANCOVA) were used The Mantel-Haenszel chi-square test was used to analyze hyperinsulinemia, seizure freedom and the stress questionnaire with 95% confidence intervals around the odds ratios. Menstrual cycle frequency was analyzed using loglinear poisson regression to construct a 95% confidence interval around the treatment difference. The log exposure time (in number of cycles) was used as the offset function. Study Population: Females, 13 to 40 years of age who: had a confident diagnosis of epilepsy and were: newly diagnosed with less than 2 weeks of treatment for seizures or had inadequately controlled epilepsy while receiving a single chronic AED had regular menstrual cycles were not using hormonal medication were not pregnant, less than 6 months post-partum, or breast-feeding had BMI equal or less than 35 kg/m 2 had never received or Number of Subjects: Planned, N Randomised, N Completed, n (%) 170 (77) 170 (76) Total Number Subjects Withdrawn, n (%) 52 (23) 55 (24) Withdrawn due to Adverse Events n (%) 9 (4) 9 (4) Withdrawn due to Lack of Efficacy n (%) 2 (<1) 1 (<1) Withdrawn for other reasons n (%) 41 (18) 45 (20) Demographics N (ITT Population) Females (%) Mean Age, years (SD) 21.9 (6.4) 22.8 (7.2) White, n (%) 106 (53) 105 (50) Primary Efficacy Results (ITT Population): Proportion exhibiting symptoms of PCOS (ovulatory dysfunction or hyperandrogenism) p-value PCOS Symptoms (38) (54) Secondary Outcome Variables: All using ITT Population, with the exception of the aggravation of PCOS Symptoms endpoint, which uses the Screen PCOS Population 95% CI Subjects with treatment-emergent PCO (40) (40) (0.358,1.590) Subjects with PCOS, n (%) (2) (9) (0.050, 0.698) Subjects with anovulatory menstrual cycles (20) (31) (0.310, 0.933) 2
3 Menstrual irregularities (frequency, length, regularity) Frequency, % Mean (SD) (15.94) Length, days Mean (SD) (10.34) Regularity, days Mean (SD) (18.84) 95% n Value n Value CI (16.22) (4.55) (15.76) (0.944, 1.063) - (95% CI) 0.1 (-1.2, 1.4) -0.2 (-3.6, 3.2) Serum Androgens and SHBG n Value n Value - (95% CI) Total Testosterone, ng/dl Mean (SD) change (14.8) (-10.1,-3.6) (17.0) Free Testosterone, ng/dl Mean (SD) change (0.012) (0.012) ( , ) Androstenedione, ng/dl Mean (SD) change (1.8) (2.3) DHEA-S, ug/dl Mean (SD) change (57.6) (54.2) SHBG, nmol/l Mean (SD) change (32.3) LH, IU/L Mean (SD) change (6.62) FSH, IU/L Mean (SD) change (7.25) LH:FSH, IU/L Mean (SD) change (1.23) Serum Lipids (41.7) (5.04) (2.64) (0.70) (-0.478, 0.390) 28.0 (15.4, 40.6) (-23.8, -8.4) (-1.33, 0.61) 0.55 (-0.62, 1.72) (-0.22, 0.18) Difference Between n Value n Value - (95% CI) Total Cholesterol, mg/dl Mean (SD) change (29.9) (27.7) 2.2 (-3.2, 7.6) HDL Cholesterol, mg dl Mean (SD) change (10.0) (9.1) 3.4 (1.5, 5.3) LDL Cholesterol, mg/dl Mean (SD) change (22.6) (21.8) 0.7 (-3.4, 4.9) 3
4 Triglycerides, mg/dl Mean (SD) change (36.0) (37.1) -9.2 (-16.5, -2.0) Insulin Difference Between n Value n Value - (95% CI) Fasting Insulin, µiu/ml Mean (SD) change (8.62) hours post-dose Insulin, µiu/ml Mean (SD) change (18.68) (62.90) (59.36) (-4.52, 0.57) (-13.27, 11.86) Odds Ratio (95% CI) Subjects with Hyperinsulinemia (6) (40) (0.255,1.49) Weight and BMI n Value n Value - (95% CI) Weight, kg Mean (SD) change (3.6) (4.2) (-3.45, -1.86) BMI, kg/m 2 Mean (SD) change (1.5) (1.7) (-1.35, -0.71) Seizure Freedom, n (%) Odds Ratio (95% CI) All Subjects 75 (37) 98 (46) (0.469, 1.059) Newly Diagnosed Subjects 60 (38) 87 (48) Subjects with Inadequately Controlled Seizures 15 (37) 11 (35) Quality of Life Measures n Value n Value - (95% CI) SEALS Total Score Mean (SD) change (17.46) (16.70) (-18.46, 17.89) Odds Ratio (95% CI) Stress Questionnaire Mean (SD) change (23) (16) (-1.35, -0.71) Aggravation of Symptoms of PCOS Serum Androgens and SHBG N=18 N=11 n Value n Value - (95% CI) Total Testosterone, ng/dl Mean (SD) change (15.6) (22.5) -6.9 (-20.2, 6.5) Free Testosterone, ng/dl Mean (SD) change (0.024) (0.018) ( , ) 4
5 DHEA-S, ug/dl Mean (SD) change (58.8) (85.3) 51.2 (-5.9, 108.3) Safety Results (Safety Population): AEs and SAEs were collected from start of therapy through 3 weeks post discontinuation of study medication. (N=219) (N=222) Most Frequent Adverse Events On-Therapy n (%) n (%) Subjects with any AE(s), n(%) 123 (56) 122 (55) Headache 29 (13) 39 (18) Pyrexia 15 (7) 13 (6) Nasopharyngitis 12 (5) 11 (5) Dizziness 11 (5) 10 (5) All Rash 1 10 (5) 9 (4) Abdominal Pain 6 (3) 3 (1) Vomiting 6 (3) 16 (7) Asthenia 5 (2) 0 Influenza 5 (2) 2 (<1) Pharyngitis 5 (2) 3 (1) Dysmennorhea 5 (2) 1 (<1) Alopecia 3 (1) 25 (11) Tremor 2 (<1) 18 (8) Nausea 3 (1) 16 (7) Weight Increase 0 11 (5) 1 All Rash consists of Angioneurotic Edema, Erythema Multiforme, Rash, Rash Macular, Rash Morbilliform, Rash Papular and Urticaria Serious Adverse Events - On-Therapy n (%) [n considered by the investigator to be related to study medication] Non-fatal SAEs Any Subject 5 (2) [1] 8 (4) [1] Convulsion 1 (<1) [0] 0 Dizziness 1 (<1) [0] 0 Encephalopathy 1 (<1) [1] 1 (<1) [1] Myoclonic epilepsy 1 (<1) [0] 0 Asthenia 1 (<1) [0] 0 Tuberculosis 1 (<1) [0] 0 Joint Injury 1 (<1) [0] Dyskinesia 0 1 (<1) [1] Grand Mal convulsion 0 2 (<1) [0] Sensory disturbance 0 1 (<1) [0] Somnolence 0 1 (<1) [0] Hepatitis A 0 1 (<1) [0] Hyperammonaemia 0 1 (<1) [1] Abortion, spontaneous 0 1 (<1) [0] Suicide attempt 0 1 (<1) [0] Calculus ureteric 0 1 (<1) [0] Cervical dysplasia 0 1 (<1) [0] Metrorrhagia 0 1 (<1) [0] Fatal SAEs, n (%) Any Subject 0 0 5
6 Conclusion: In this open label study, significantly fewer women with epilepsy developed PCOS symptoms while receiving therapy with compared to those receiving therapy with for up to 1 year. Publications: Abstract: Higher incidence of components of polycystic ovary syndrome in young women with epilepsy treated with valproate versus lamotrigine. Morrell, Martha J MD, Hayes, Frances S MD, Sluss, Patrick M PhD, Warnock, Clay R, Conklin, Heather S, and Isojarvi, Jouko I. MD PhD 3 59th Annual Meeting of the American Epilepsy Society held jointly with the American Clinical Neurophysiology Society 12/2/2005 Washington, DC; USA Abstract: Higher incidence of components of polycystic ovary syndrome in young women with epilepsy treated with valproate versus lamotrigine. Morrell, M. J., Hayes, F. J., Sluss, P., Warnock, C. R., and Isojarvi, J. I. T. 26th International Epilepsy Congress 8/28/2005 Paris; France Abstract: Higher incidence of symptoms of polycystic ovary syndrome in women with epilepsy treated with valproate versus lamotrigine. Morrell, Martha, Bhatt, Mohitt, Ozkara, Cigdem, Hayes, Frances, Sluss, Patrick, Adams, Judith, Warnock, Clay R., and Isojarvi, Jouko 57th Annual Meeting of the American Academy of Neurology 4/9/2005 Miami Beach, FL; USA Abstract: Reproductive endocrine characteristics of women with newly diagnosed or inadequately controlled epilepsy: a preliminary analysis. M Bar, R Borgohain F Hayes C. R Warnock H Co 6th European Congress on Epileptology 5/30/2004 Vienna; Austria Abstract: Reproductive endocrine characteristics of women with newly diagnosed or inadequately controlled epilepsya preliminary analysis. Rupam Borgohain MBBS, DM Michal Bar MD Frances Hayes MD Clay R. Warnock Heather Conklin Sarah Jarman and Martha Morrell MD. 1 57th Annual Meeting of the American Epilepsy Society 12/5/2003 Boston, MA; USA Date Updated: 30-Oct
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More information18 y.o. female with amenorrhea. Olesya Krivospitskaya, MD Endorama 08/08/2013
18 y.o. female with amenorrhea Olesya Krivospitskaya, MD Endorama 08/08/2013 History of past illness: 18 y.o. female presented for the evaluation of a secondary amenorrhea Menarche at 12 Irregular menstrual
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationLondon, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION
London, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION 1/15 EMEA 2006 1. Introduction Epilepsy is one of the most common and challenging neurological disorders.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationGSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview
INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences PBL MBBS III VJ Temple 1 Insulin Resistance: What is
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWhat is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this...
PCOS What is PCOS? You'll be amazed when you read this... What is PCOS?. Who is at risk? How to get tested? What are the complications. Is there a cure? What are the right ways to eat? What lifestyle changes
More informationPCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS
PCOS Awareness Symposium Atlanta September 24 th, 2016 Preventing Diabetes & Cardiovascular Disease in PCOS Katherine Sherif, MD Professor & Vice Chair, Department of Medicine Director, Jefferson Women
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMetformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study
The Journal of Obstetrics and Gynecology of India (September-October 2012) 62(5):551 556 DOI 10.1007/s13224-012-0183-3 ORIGINAL ARTICLE Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationMetfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study
Original Research Article Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study Allanki Suneetha Devi 1, Jalem Anuradha 2* 1 Associate Professor, Department of Obstetrics and Gynecology,
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationCARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME
CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME Enrico Carmina Executive Director & CEO of Androgen Excess & PCOS Society Professor of Endocrinology Department of Health Sciences and Mother and Child
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationReproductive hormones and epilepsy
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 7 Treatment of women with epilepsy - Level 1-2 Reproductive hormones and epilepsy Gerhard
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationStudy No.: 49653/020 Title: A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of
Study No.: 49653/020 Title: A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone vs. Glibenclamide Therapy, When Administered
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor / Company: Sanofi Drug substance(s): AMARYL M (1/250 mg) / HOE490
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia
Page 1 Sponsor Novartis Generic Drug Name Fluvastatin Therapeutic Area of Trial Dyslipidemia Approved Indication Therapeutic area and approved indications in Germany: Hypercholesterolemia (HC), combined
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
he study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationROKSANA KARIM, MBBS, PHD UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES, CA
Gonadotropin and Sex Steroid Levels in HIVinfected Premenopausal Women and Their Association with Subclinical Atherosclerosis in HIVinfected and -uninfected Women in the Women s Interagency HIV Study (WIHS)
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationAntim ullerian hormone and polycystic ovary syndrome
Antim ullerian hormone and polycystic ovary syndrome Yi-Hui Lin, M.D., a Wan-Chun Chiu, Ph.D., c Chien-Hua Wu, Ph.D., b,e Chii-Ruey Tzeng, M.D., d Chun-Sen Hsu, M.D., a and Ming-I Hsu, M.D. a a Department
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid
More informationSecondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPOLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015
POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility Based on: ACOG No. 108 Oct 2009; reaffirmed 2015 NO DISCLOSURES PATIENT 26 years old presents with complaint of
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationStudy No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the Investigation and Management of Polycystic Ovary Syndrome Author: Contact Name and Job Title
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More information2011 MNA Midwest Summer Conference
2011 MNA Midwest Summer Conference Women and Epilepsy Marianna V. Spanaki, M.D., Ph.D., M.B.A. SENIOR STAFF NEUROLOGIST DIRECTOR EPILEPSY MONITORING UNIT HENRY FORD COMPREHENSIVE EPILEPSY PROGRAM HENRY
More informationSecondary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Group 1 (Test Group) Group 2 (Reference group):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWomen s Issues in Epilepsy. Esther Bui, Epilepsy Fellow MD, FRCPC
Women s Issues in Epilepsy Esther Bui, Epilepsy Fellow MD, FRCPC How are women different? Different habitus Different metabolism Different co-morbidities Different psychosocial stigma Different hormonal
More informationStudy No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods: Sample Size
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPCOS and Obesity DUB is better treated by OCPs
PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One
More information12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND
Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND 7% of all women 18-45 Obesity 1/3 of all US women Incidence of PCOS is increasing with increase obesity Obesity Irregular
More informationSYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:
SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled
More information